Document is current
Any future updates will be listed below
-
Authors
Qin, Xunsi https://orcid.org/0000-0002-5869-8873
Zhao, Yue https://orcid.org/0000-0002-3016-9654
Zhang, Tianyi
Yin, Chenghong
Qiao, Jie https://orcid.org/0000-0003-2126-1376
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology of the People’s Republic of China (2017YFE0126500)
National Natural Science Foundation of China (81501105)
National Natural Science Foundation of China (31730034)
Beijing Municipal Science and Technology Commission (Z151100003915118)
- License Information
-
More Information
Article History
Received: 24 July 2020
Accepted: 12 January 2022
First Online: 17 February 2022
Competing interests
: B.L. and W.G. are co-inventors of the filed patents related to the TrkB agonistic antibodies. B.L. is also a co-founder and Scientific Advisor of 4B Technologies, Limited, a biotech company that develops medicines for neurodegenerative diseases. The remaining authors declare no competing interests.
